Abbott LaboratoriesABTNYSE
Loading
EPS Growth Recovery in ProgressRecovering
Percentile Rank56
5Y CAGR-35.2%
Year-over-Year Change
Year-over-year earnings per share growth rate
5Y CAGR
-35.2%/yr
Long-term compound
Percentile
P56
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 8.51% |
| Q3 2025 | -7.84% |
| Q2 2025 | 34.50% |
| Q1 2025 | -85.77% |
| Q4 2024 | 461.05% |
| Q3 2024 | 26.67% |
| Q2 2024 | 5.63% |
| Q1 2024 | -22.83% |
| Q4 2023 | 10.84% |
| Q3 2023 | 5.06% |
| Q2 2023 | 3.95% |
| Q1 2023 | 28.81% |
| Q4 2022 | -28.05% |
| Q3 2022 | -28.70% |
| Q2 2022 | -17.86% |
| Q1 2022 | 23.89% |
| Q4 2021 | -5.04% |
| Q3 2021 | 77.61% |
| Q2 2021 | -33.66% |
| Q1 2021 | -17.21% |
| Q4 2020 | 74.29% |
| Q3 2020 | 133.33% |
| Q2 2020 | -6.25% |
| Q1 2020 | -46.67% |
| Q4 2019 | 11.11% |
| Q3 2019 | -5.26% |
| Q2 2019 | 50.00% |
| Q1 2019 | 2.70% |
| Q4 2018 | 15.62% |
| Q3 2018 | -23.81% |
| Q2 2018 | 75.00% |
| Q1 2018 | 151.06% |
| Q4 2017 | -234.29% |
| Q3 2017 | 118.75% |
| Q2 2017 | -33.33% |
| Q1 2017 | -55.56% |
| Q4 2016 | 345.45% |
| Q3 2016 | -152.38% |
| Q2 2016 | 90.91% |
| Q1 2016 | -57.69% |